Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542313 | 1.00 | POLB (0.33) | POLBPKMKDM4EHTTGAA | |
| SCHEMBL5792577 | 0.85 | POLB (0.35) | POLBPKMLMNAALDH1A1KDM4C | |
| SCHEMBL5789836 | 0.76 | GSK3B (0.48) | GAAHPGD | |
| SCHEMBL5865515 | 0.76 | ALDH1A1 (0.40) | KDM4EHTTGAASMN1; SMN2MAPT | |
| SCHEMBL5789834 | 0.76 | GSK3B (0.48) | GAAHPGD | |
| SCHEMBL5865514 | 0.76 | ALDH1A1 (0.40) | KDM4EHTTGAASMN1; SMN2MAPT | |
| SCHEMBL6542715 | 0.72 | RXRA (0.46) | MEN1KMT2A | |
| SCHEMBL6542709 | 0.72 | RXRA (0.46) | MEN1KMT2A | |
| SCHEMBL5865777 | 0.71 | ALDH1A1 (0.59) | HTTGAASMN1; SMN2MAPTLMNA | |
| SCHEMBL6541637 | 0.65 | RXRA (0.36) | POLBKDM4EGAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421061-A4 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INC (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | POLB 1445/4885PKM 450/4885KDM4E 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.